In 39-Mseq cohort, 8 out of 39 patients carried focal amplifications of CDK6; of which, amplifications in 7 patients were ubiquitous, highlighting the importance of CDK6 as a potential druggable target for all tumor cells (TCs) for CDK6-amplified patients. The gene discussed is CDK6; the disease is neoplasm.